Basilea partner Asahi Kasei Therapeutics starts Japan Phase 2 pediatric Cresemba trial

• Basilea reported partner Asahi Kasei Therapeutics started a Phase 2 pediatric Cresemba trial in Japan for deep-seated fungal infection risk.
• No results have been presented; the study will generate future safety and pharmacokinetic data to support potential pediatric use in Japan.
• The open-label, single-arm design targets children vulnerable to invasive fungal disease, where treatment options remain limited.
• Cresemba is already cleared for pediatric use in the US, Canada, Europe, China; Japan currently limits it to adults.
• Global in-market sales reached USD 782 million for April 2025–March 2026, up 27%, reinforcing the brand’s commercial momentum.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140115OMX_____CNEWS_DE_GNW1001262417_de) on September 14, 2026, and is solely responsible for the information contained therein.